6317-56-2

Usage

Uses

Used in Pharmaceutical Industry:
p-(Phenylthio)benzyl alcohol is used as an impurity in the production of Fenticonazole nitrate (F279250), a new and potent antimycotic compound. Its presence in the manufacturing process is crucial for the development of this effective antifungal agent, which can be used to treat a wide range of fungal infections.
Used in Chemical Synthesis:
Due to its unique chemical structure, p-(phenylthio)benzyl alcohol can be utilized as a building block or intermediate in the synthesis of various organic compounds. Its reactivity and functional groups make it a valuable component in the creation of new molecules with potential applications in various fields, such as materials science, pharmaceuticals, and agrochemicals.
Used in Research and Development:
p-(Phenylthio)benzyl alcohol can also be employed as a research tool in the study of organic chemistry, particularly in the investigation of reactions involving thiol and alcohol functional groups. Its use in research can lead to a better understanding of reaction mechanisms and the development of new synthetic methods or strategies.

InChI:InChI=1/C13H12OS/c14-10-11-6-8-13(9-7-11)15-12-4-2-1-3-5-12/h1-9,14H,10H2

Upstream product

• 1208-88-4 4-phenylsulfanyl-benzaldehyde 
• 6310-24-3 4-(phenylthio)benzoic acid 
• 139-66-2 diphenyl sulfide 
• 873-75-6 4-bromobenzenemethanol 
• 108-98-5 thiophenol 
• 18282-51-4 4-iodo-benzyl alcohol 
• 59016-93-2 p-hydroxymethylphenylboronic acid 
• 1122-91-4 4-bromo-benzaldehyde 
• 39248-81-2 methyl 4-phenylthiobenzoate 

Downstream Products

• 1208-87-3 1-phenylthio-4-chloromethyl-benzene 
• 100-51-6 benzyl alcohol 
• 1093117-21-5 (4-(bromomethyl)phenyl)(phenyl)sulfide 
• 6310-24-3 4-(phenylthio)benzoic acid 
• 66-39-7 4-(phenylsulfonyl)benzaldehyde 
• 72479-26-6 α-(2,4-dichlorophenyl)-β,N-imidazolylethyl 4-phenylthiobenzyl ether 
• 6317-59-5 1-cyanomethyl-4-phenylthiobenzene 
• 85554-28-5 (4-benzenesulfonyl-phenyl)-acetonitrile 
• 898535-26-7 methanesulfonic acid 4-phenylsulfanyl-benzyl ester 

Relevant academic research and scientific papers

Method for synthesizing fenticonazole nitrate

The invention belongs to the technical field of chemical synthesis, and discloses a method for synthesizing fenticonazole nitrate. By the aid of a phase transfer catalytic method, condensation reaction is performed at the presence of sodium hydroxide. The method particularly includes the steps: 1) synthesizing 4-mercaptophenyl-benzaldehyde; 2) synthesizing 4-mercaptophenyl benzyl alcohol; 3) synthesizing 4-mercaptophenyl-benzyl chloride; 4) synthesizing fenticonazole nitrate crude products. Used reagents are low in cost and easy to obtain, synthesis cost is greatly reduced, operation is simpleand convenient, special requirements on equipment are omitted, and the method is more suitable for scale production.

Refining process, detection standard and application of fenticonazole nitrate

The invention belongs to the technical field of chemical synthesis and discloses a refining process of fenticonazole nitrate. The refining process comprises the following steps: 1) synthesizing an intermediate I, namely 4-benzene sulfydryl benzaldehyde; 2) synthesizing an intermediate II, namely 4-benzene sulfydryl phenylcarbinol; 3) synthesizing an intermediate III, namely 4-benzene sulfydryl benzyl chloride; 4) synthesizing a crude product of fenticonazole nitrate; and 5) refining fenticonazole nitrate. The invention further discloses a detection method of an intermediate of the fenticonazole nitrate and an application of the fenticonazole nitrate in medicines.

Synthesis process of fenticonazole nitrate

The invention belongs to the technical field of chemical synthesis, and discloses a synthesis process of fenticonazole nitrate. The synthesis process comprises the following steps: 1) synthesis of intermediate I:4-phenylthio-benzaldehyde; 2) synthesis of intermediate II:4-phenylthio benzyl alcohol; 3) synthesis of intermediate III:4-phenylthio benzyl chloride; 4) synthesis of crude fenticonazole nitrate; 5) refining of the fenticonazole nitrate; 6) preparation of suppository. The synthetic process is simple and feasible and suitable for popularization and use, and has broad market applicationprospects.

Chan-lam-type s-arylation of thiols with boronic acids at room temperature

In this work, an efficient CuSO4-catalyzed S-arylation of thiols with aryl and heteroaryl boronic acids at room temperature is established. This catalytic system can tolerate a wide variety of thiols and arylboronic acids in the presence of only 5 mol % of CuSO4 as the catalyst and inexpensive 1,10-phen?H2O as the ligand. Moreover, this catalytic system used environment-friendly solvent (EtOH) and oxidant (oxygen).

Non-basic ligands for aminergic GPCRs: The discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists for the treatment of sleep disorders

Scaffold hopping from a non-basic series of 5-HT2A receptor antagonists developed in-house that possessed reduced activity in vivo enabled the discovery of a novel series of diaryl sulfones that gave excellent occupancy on oral dosing. Not only does this work further demonstrate that oral bioavailability of a given series can be enhanced by improving physicochemical parameters such as log P, but it corroborates the growing evidence that a protonated amine is not essential for affinity at aminergic GPCRs.

A general, efficient, and functional-group-tolerant catalyst system for the palladium-catalyzed thioetherification of aryl bromides and iodides

The cross-coupling reaction of aryl bromides and iodides with aliphatic and aromatic thiols catalyzed by palladium complexes of the bisphosphine ligand CyPF-tBu (1) is reported. Reactions occur in excellent yields, broad scope, high tolerance of functional groups, and with turnover numbers that exceed those of previous catalysts by 2 or 3 orders of magnitude. These couplings of bromo- and iodoarenes are more efficient than the corresponding reactions of chloroarenes and could be conducted with less catalyst loading and/or milder reaction conditions. Consequently, limitations regarding scope and functional group tolerance previously reported in the coupling of aryl chlorides are now overcome.

Characterization of novel sulfonium photoacid generators and their microwave-assisted synthesis

Microwave-assisted synthesis of triarylsulfonium salt photoacid generators (PAGs) afforded reaction times 90 to 420 times faster than conventional thermal conditions, with photoacid quantum yields of new sulfonium PAGs ranging from 0.01 to 0.4. The Royal Society of Chemistry.

Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors

Various sulfonyl-containing compounds (e.g. sulfonamides, sulfones) bind at human 5-HT6 serotonin receptors, but it has been difficult relating the binding mode(s) of such agents to one another, even though many possess a common SO2 moiety, to identify a common pharmacophore model(s). On the basis of the hypothesis that an ergoline-type conformation might be important for the binding of some sulfonamide-containing arylalkylamines, we prepared for examination at h5-HT6 receptors a series of compounds, including phenylethylamines 6, pyrroloethylamine 7, and phenylpiperazines 9. The results (with Ki values ranging from about 1 nM to > 1000 nM) suggest that many of these agents likely bind in a related fashion, and structure-affinity studies indicate that the benzenesulfonamide portion of the phenylethylamine and phenylpiperazine analogues can be "reversed", abbreviated to a sulfone, and moved to an adjacent position with relatively little impact on affinity. Although a benzenesulfonamide (or related arylsulfonamide) group might be common to various 5-HT6 ligands, there appears to be some latitude with regard to the specific constitution and location of the sulfonamide moiety even within the same arylalkylamine structural framework. A pharmacophore model is presented to account for some of the current findings.

Pyrimidine derivatives, method of manufacturing the same, and androgen inhibitor

The invention discloses a pyrimidien derivative expressed in Formula [I]: STR1 where R 1 denotes a hydrogen atom or hydroxyl group, R 2 denotes a hydrogen atom, lower alkoxycarbonyl group, lower alkoxy group, halogen atom, lower alkyl group, cycloalkyl group with 3 to 8 carbon atoms, lower alkoxycarbonyl lower alkyl group, carboxyl group, carboxy lower alkyl group, group: --CONHR 6 (R 6 represents a hydrogen atom, a phenyl group, which may possess halogen atom, or lower alkyl group), cyano group, phenyl group which may possess a group selected from the group consisting of hydroxyl group, halogen atom, lower alkyl group, lower alkoxy group and phenylthio group as a substituent, phenyl lower alkyl group which may possess a group selected from the group consisting of hydroxyl group and lower alkoxy group as a substituent on a phenyl ring, lower alkanoyloxy lower alkyl group, benzoyl group, lower alkanoyl group which may possess a halogen atom, or hydroxy lower alkyl group which may possess a group selected from the group consisting of phenyl group and halogen atom as a substituent, R 3 denotes a hydrogen atom, hydroxyl group, lower alkyl group, cycloalkyl group with 3 to 8 carbon atoms, halogen lower alkyl group, or phenyl group, R 4 denotes a hydrogen atom, lower alkyl group, or lower alkoxy group, and R 5 denotes a hydrogen atom, lower alkyl group, lower alkoxy lower alkyl group, or halogen lower alkyl group; provided that R 2 and R 3 may be bonded to each other to form a lower alkylene group with 3 to 5 carbon atoms, or its pharmaceutically available salt. This derivative is excellent in therapeutic effects of benign prostatic hypertrophy, prostatic carcinoma, female hairiness, male baldness or pimple as an androgen inhibitor.

Pyrazolotriazine compounds

Pyrazolotriazine compounds of the formula: STR1 wherein R1 is OH or alkanoyloxy; R2 is H, OH, or SH; R3 is (1) unsaturated N- or S-containing heterocyclic group optionally having 1-2 substituents of halogen, nitro or phenylthio, (2) naphthyl, (3) phenyl optionally having 1-3 substituents of (i) alkyl, (ii) phenyl, (iii) alkoxycarbonyl, (iv) cyano, (v) nitro, (vi) alkoxy, (vii) phenylalkoxy (viii) phenylthio-alkyl, (ix) phenoxy, (x) STR2 R is alkyl, halo-substituted alkyl, phenyl optionally having 1-3 substituents, or pyridyl, and l is 0, 1 or 2, (xi) halogen, (xii) phenylalkyl, (xiii) carboxy, (xiv) alkanoyl, (xv) benzoyl optionally having 1-3 substituents, (xvi) amino, (xvii) OH, (xviii) alkanoyloxy, (xix) STR3 or (xx) STR4 (A is alkylene), said compounds having a xanthine oxidase inhibitory activity and are useful for the prophylaxis and treatment of gout.